Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for non-functioning pituitary adenomas
2012-001338-32Phase 4Active
- Sponsor
- St. Olavs University Hospital
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cabergoline in chromophobe adenoma (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Change in tumor volume. Started May 2012; status: active.
02
Drugs
cabergoline
03
Conditions
chromophobe adenoma
Beyond the preview
Go deeper on 2012-001338-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001338-32.